Blueprint Medicines Corporation

Symbol: 0HOJ.L

LSE

103.975

USD

Market price today

  • -21.9523

    P/E Ratio

  • -1.5084

    PEG Ratio

  • 6.51B

    MRK Cap

  • 0.00%

    DIV Yield

Blueprint Medicines Corporation (0HOJ-L) Financial Statements

On the chart you can see the default numbers in dynamics for Blueprint Medicines Corporation (0HOJ.L). Companys revenue shows the average of 145.351 M which is 1.209 % gowth. The average gross profit for the whole period is 82.768 M which is 0.752 %. The average gross profit ratio is -0.997 %. The net income growth for the company last year performance is -0.091 % which equals -0.407 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Blueprint Medicines Corporation, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.223. In the realm of current assets, 0HOJ.L clocks in at 808.393 in the reporting currency. A significant portion of these assets, precisely 710.641, is held in cash and short-term investments. This segment shows a change of -0.341% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 94.557, if any, in the reporting currency. This indicates a difference of -41.367% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 610.962 in the reporting currency. This figure signifies a year_over_year change of 0.151%. Shareholder value, as depicted by the total shareholder equity, is valued at 130.609 in the reporting currency. The year over year change in this aspect is -0.746%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 43.178, with an inventory valuation of 21.22, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0. Account payables and short-term debt are 4.71 and 81.41, respectively. The total debt is 774.12, with a net debt of 702.84. Other current liabilities amount to 127.99, adding to the total liabilities of 918.64. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013

balance-sheet.row.cash-and-short-term-investments

2794.16710.61078.51034.6
1549.7
548
494
673.4
268.2
162.7
47.2
2

balance-sheet.row.short-term-investments

2478.05639.4825.3267.2
187.2
369.6
425.9
273.1
162.1
0
0
0

balance-sheet.row.net-receivables

182.7543.236.937
25.3
23.4
0
0
3.6
3.4
0
0

balance-sheet.row.inventory

85.6421.229.721.8
8.6
-434
0
0
-54.1
0
0
0

balance-sheet.row.other-current-assets

141.9633.435-539.5
-655.9
379.4
5.8
12.1
2.7
4.3
1
0.5

balance-sheet.row.total-current-assets

3204.5808.41046.7554
927.8
516.8
499.8
685.5
220.4
170.4
48.3
2.4

balance-sheet.row.property-plant-equipment-net

459.14115.7115.2120.9
101.7
111.1
29.6
24.4
6.2
6.7
1.5
1.4

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

520.4894.6161.3557.5
677.9
64.4
0
0
54.1
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

115.3430.626.819.8
11.1
15.4
10.7
5.9
2.1
1.8
0.2
0.3

balance-sheet.row.total-non-current-assets

1094.97240.9303.3698.2
790.6
190.9
40.3
30.2
62.4
8.5
1.7
1.7

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

4299.471049.31349.91252.2
1718.4
707.7
540.1
715.7
282.8
178.9
49.9
4.1

balance-sheet.row.account-payables

23.584.72.78.3
4.4
4.8
3.3
3.7
2.2
2.5
0.8
1.4

balance-sheet.row.short-term-debt

303.0981.427.48.1
7.9
6.8
1.7
3.2
3.1
3.8
1.7
0.7

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

2187.5611215103.3
81.7
89.1
14.6
16.3
3.4
3.9
7.3
2.2

Deferred Revenue Non Current

19.434.8426.725.1
41.2
46.1
46.2
35.4
47.2
13.6
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

331.32---
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

446.87128-295.596.8
105.9
88.7
51.7
30.5
11.7
6.4
0.3
0

balance-sheet.row.total-non-current-liabilities

2556.49703.7652131.7
117.5
136.9
60.8
48.9
41.2
16.3
7.7
2.5

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

331.3281.8103.4111.4
89.6
95.9
14.6
16.3
3.4
3.9
0
0

balance-sheet.row.total-liab

3344.43918.6835.2281.5
248.3
243.3
121.1
91.8
69.7
34.9
14.5
5.6

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
178.9
114.8
40

balance-sheet.row.common-stock

0.250.10.10.1
0.1
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-8915.08-2339.9-1833-1275.4
-631.4
-945.2
-597.5
-355.6
-207.5
-135
-82.2
-41.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

-14.25-3.5-10.4-4.1
-5.2
-2.5
-0.2
-0.3
0
-2.1
-1.5
-0.9

balance-sheet.row.other-total-stockholders-equity

9884.12247423582250.3
2106.6
1412.1
1016.7
979.8
420.5
102.1
4.4
1.4

balance-sheet.row.total-stockholders-equity

955.04130.6514.7970.7
1470.1
464.4
419
624
213.1
144
35.4
-1.5

balance-sheet.row.total-liabilities-and-stockholders-equity

4299.471049.31349.91252.2
1718.4
707.7
540.1
715.7
282.8
178.9
49.9
4.1

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

955.04130.6514.7970.7
1470.1
464.4
419
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

4299.47---
-
-
-
-
-
-
-
-

Total Investments

2998.53733.9958.8824.7
865.1
434
425.9
273.1
216.1
0
0
0

balance-sheet.row.total-debt

2821.92774.1242.5111.4
89.6
95.9
14.6
16.3
3.4
3.9
9
2.9

balance-sheet.row.net-debt

2505.81702.8122.7-98.5
-595
-18
-53.4
-657
-264.8
-158.8
-38.2
0.9

Cash Flow Statement

The financial landscape of Blueprint Medicines Corporation has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.114. The company recently extended its share capital by issuing 21.34, marking a difference of 1.667 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 1.88 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 274040000.000 in the reporting currency. This is a shift of -2.833 from the previous year. In the same period, the company recorded 11.66, 290.1, and -97.93, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as -0.04, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013

cash-flows.row.net-income

-288.29-507-557.5-644.1
313.9
-347.7
-236.6
-148.1
-72.5
-52.8
-40.3
-20.9

cash-flows.row.depreciation-and-amortization

17.3511.720.112.8
12.3
10.3
4.2
1.6
1.6
0.9
0.6
0.5

cash-flows.row.deferred-income-tax

-59.6-126.1-87.8-67.3
-67
-31.5
-30.7
-15.7
0
-1.8
0
0

cash-flows.row.stock-based-compensation

93.792.79991.6
75.5
54.7
30.5
12.5
6.1
5.2
2.3
0.4

cash-flows.row.change-in-working-capital

-57.91-41.1-53.8-23.7
-15.6
9.7
0.2
3.2
0
-3.4
0
0

cash-flows.row.account-receivables

-29.94-7.7-2.2-11.8
-1.9
-23.2
0.2
3.2
0
-3.4
0
0

cash-flows.row.inventory

-1.75-4.4-8.9-12.6
-6.7
0
0
0
0
0
0
0

cash-flows.row.account-payables

-5.611.9-5.84.2
-0.8
1.4
0
0
0
0
0
0

cash-flows.row.other-working-capital

-20.61-31-36.8-3.5
-6.3
31.5
0
0
0
0
0
0

cash-flows.row.other-non-cash-items

-14.55133.177.8332
67.9
26.5
57.4
11
40.3
18.4
1.9
1

cash-flows.row.net-cash-provided-by-operating-activities

-415.4000
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-14.58-16.1-8.9-3.1
-3.2
-14
-12.7
-15.5
-2.4
-4.9
-0.7
-0.3

cash-flows.row.acquisitions-net

-114.73-290.10-258.2
431.1
2.5
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-833.65-766.4-489.7-655.4
-969.4
-738.4
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

1026.621056.5349.4690.8
538.3
735.9
0
0
0
0
0
0

cash-flows.row.other-investing-activites

192.96290.1-0.30
-431.1
-2.5
-148.4
-56.8
-216.5
-1.2
0
0

cash-flows.row.net-cash-used-for-investing-activites

178.38274-149.5-225.9
-434.2
-16.5
-161.1
-72.3
-218.8
-6.1
-0.7
-0.3

cash-flows.row.debt-repayment

-98.37-97.9-553.60
0
0
-1.5
-2.6
-3.3
-1.8
-0.8
0

cash-flows.row.common-stock-issued

88.6721.38.250.7
617.8
340.8
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

103.28042450.7
617.8
-0.1
6
546.5
135.9
155
82.1
18

cash-flows.row.net-cash-used-provided-by-financing-activities

186.19119.2561.850.7
617.8
340.6
4.5
543.9
132.6
153.2
81.4
18

cash-flows.row.effect-of-forex-changes-on-cash

-0.140.2-0.2-0.9
-0.3
0
0
0
1.4
0
0
3.3

cash-flows.row.net-change-in-cash

-56.4-48.4-90.2-474.7
570.2
46.2
-331.6
351.7
-109.4
115.5
45.3
2

cash-flows.row.cash-at-end-of-period

316.1171.3119.7209.9
684.6
114.4
73.4
405.1
53.3
162.7
47.2
2

cash-flows.row.cash-at-beginning-of-period

372.51119.7209.9684.6
114.4
68.3
405.1
53.3
162.7
47.2
2
0

cash-flows.row.operating-cash-flow

-415.4-436.8-502.3-298.7
387
-278
-175
-119.9
-24.5
-31.7
-35.4
-19

cash-flows.row.capital-expenditure

-14.58-16.1-8.9-3.1
-3.2
-14
-12.7
-15.5
-2.4
-4.9
-0.7
-0.3

cash-flows.row.free-cash-flow

-429.98-452.9-511.2-301.7
383.9
-292
-187.7
-135.4
-26.9
-36.6
-36.1
-19.3

Income Statement Row

Blueprint Medicines Corporation's revenue saw a change of 0.222% compared with the previous period. The gross profit of 0HOJ.L is reported to be 224.92. The company's operating expenses are 711.2, showing a change of 2.375% from the last year. The expenses for depreciation and amortization are 11.66, which is a -0.420% change from the last accounting period. Operating expenses are reported to be 711.2, which shows a 2.375% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.095% year-over-year growth. The operating income is -486.28, which shows a -0.095% change when compared to the previous year. The change in the net income is -0.091%. The net income for the last year was -506.98.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013

income-statement-row.row.total-revenue

282.21249.4204180.1
793.7
66.5
44.5
21.4
27.8
11.4
0
0

income-statement-row.row.cost-of-revenue

28.9124.546.938.5
12.8
0
243.6
144.7
81.1
48.6
31.8
15.9

income-statement-row.row.gross-profit

253.3224.9157.2141.6
781
66.5
-199.1
-123.3
-53.4
-37.2
-31.8
-15.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

393.25---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

62.37---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

16.9---
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

694.19711.2694.7783.5
472.3
417.6
43.7
27.7
19.5
14.9
8
4.8

income-statement-row.row.cost-and-expenses

723.1735.7741.6822.1
485
427.8
287.3
172.4
100.7
63.5
39.8
20.8

income-statement-row.row.interest-income

36.0932.817.72.4
6.6
13.7
6.2
2.9
0.4
0.7
0.5
0.1

income-statement-row.row.interest-expense

54.9651.616.80
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

16.9---
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

153.23-19.7-14.80.9
6.2
13.6
10.4
3.1
0.1
-1.1
-0.6
0.1

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

153.23-19.7-14.80.9
6.2
13.6
10.4
3.1
0.1
-1.1
-0.6
0.1

income-statement-row.row.interest-expense

54.9651.616.80
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

17.3511.720.112.8
12.3
10.3
4.2
1.6
1.6
0.9
0.6
0.5

income-statement-row.row.ebitda-caps

-423.55---
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-440.89-486.3-537.5-642
308.7
-361.3
-247
-151.2
-72.6
-51.6
-39.7
-21

income-statement-row.row.income-before-tax

-287.66-506-552.3-641.1
314.9
-347.7
-236.6
-148.1
-72.5
-52.8
-40.3
-20.9

income-statement-row.row.income-tax-expense

0.6315.23
1.1
0
0
0
0
3.2
5.8
2.9

income-statement-row.row.net-income

-288.29-507-557.5-644.1
313.9
-347.7
-236.6
-148.1
-72.5
-55.9
-46
-23.8

Frequently Asked Question

What is Blueprint Medicines Corporation (0HOJ.L) total assets?

Blueprint Medicines Corporation (0HOJ.L) total assets is 1049250000.000.

What is enterprise annual revenue?

The annual revenue is 168073000.000.

What is firm profit margin?

Firm profit margin is 0.898.

What is company free cash flow?

The free cash flow is -6.982.

What is enterprise net profit margin?

The net profit margin is -1.022.

What is firm total revenue?

The total revenue is -1.562.

What is Blueprint Medicines Corporation (0HOJ.L) net profit (net income)?

The net profit (net income) is -506984000.000.

What is firm total debt?

The total debt is 774122000.000.

What is operating expences number?

The operating expences are 711196000.000.

What is company cash figure?

Enretprise cash is 113326000.000.